Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 51Carcinoma, Non-Small-Cell Lung 50Carcinoma, Renal Cell 38Neoplasm Metastasis 20Carcinoma, Hepatocellular 20Lung Neoplasms 19Squamous Cell Carcinoma of Head and Neck 17Neoplasms 17Stomach Neoplasms 15Colorectal Neoplasms 15Carcinoma, Transitional Cell 14Adenocarcinoma Of Esophagus 12Prostatic Neoplasms 10Hodgkin Disease 10Brain Neoplasms 10Urinary Bladder Neoplasms 8Pancreatic Neoplasms 8Ovarian Neoplasms 8Multiple Myeloma 8Triple Negative Breast Neoplasms 7Rectal Neoplasms 7Esophageal Neoplasms 7Clear-cell metastatic renal cell carcinoma 7Breast Neoplasms 7Recurrence 6Colonic Neoplasms 6Carcinoma, Basal Cell 6Carcinoma 6Uveal Melanoma 5Uterine Cervical Neoplasms 5

Interventions

trifluridine tipiracil drug combination 1Nivolumab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Microsatellite-stable Colorectal Cancer × Nivolumab × 90 days × Clear all
NCT07011550 2026-03-20

Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer

M.D. Anderson Cancer Center

Phase 2 Suspended
7 enrolled
Gastrointestinal

Microsatellite-stable Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡